Adicet Bio, Inc.

Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States

About Adicet Bio, Inc.

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.

For more information, please visit our website at http://www.adicetbio.com.

44 articles with Adicet Bio, Inc.

Adicet Bio to Participate in Upcoming Investor Conferences - May 18, 2021

5/18/2021

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in two upcoming virtual investor conferences in May and June.
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates

5/17/2021

Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021
Adicet Bio to Participate in Fireside Chat at the 7th Annual Truist Securities Life Sciences Summit

4/29/2021

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021 at 2:40 PM ET.
Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

4/15/2021

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research

4/13/2021

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Blake Aftab, Ph.D., as Vice President of Research.
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

3/11/2021

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

3/10/2021

Company's lead candidate, ADI-001, is believed to be the first IND-cleared allogeneic CAR gamma-delta T cell therapy to reach human trials
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

3/4/2021

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Andrew Sinclair, Ph.D., to its board of directors.
Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

2/16/2021

Adicet Bio, Inc. announced the closing of an underwritten public offering of 10,575,513 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock at a public offering price of $13.00 per share.
Adicet Bio to Participate in Upcoming Investor Conferences - Feb 11, 2021

2/11/2021

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that the company management will participate in three upcoming virtual investor conferences.
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement

2/10/2021

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a public offering price of $13.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 1,344,743 shares of common stoc
Adicet Bio Prices Public Offering of Common Stock at $135 Million

2/10/2021

Adicet Bio announced pricing of an underwritten public offering of 9,230,770 shares of its common stock, marking it at a public offering per-share price of $13.00.
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

2/9/2021

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock.
Adicet Bio to Participate in Upcoming Investor Conferences - Jan 07, 2021

1/7/2021

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in two virtual investor conferences in January.
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

12/8/2020

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET. A live audio w
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors

12/1/2020

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Bastiano Sanna, Ph.D., to its Board of Directors.
Adicet Bio to Participate in Upcoming Investor Conferences

11/6/2020

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in upcoming virtual investor conferences and events in November and December. Details of the events are as follows: H.C. Wainwright 6th Annual Israel Conference Presentation on November 12, 2020 at 9:0
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update

11/5/2020

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, reported financial results for the third quarter ended September 30, 2020.
Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

10/26/2020

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer.
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell TherapyPhase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphoma

10/22/2020

Adicet Bio, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma.